Coughlin, Jennifer M.
Du, Yong
Lesniak, Wojciech G.
Harrington, Courtney K.
Brosnan, Mary Katherine
O’Toole, Riley
Zandi, Adeline
Sweeney, Shannon Eileen
Abdallah, Rehab
Wu, Yunkou
Holt, Daniel P.
Hall, Andrew W.
Dannals, Robert F.
Solnes, Lilja
Horti, Andrew G.
Pomper, Martin G. http://orcid.org/0000-0001-6753-3010
Funding for this research was provided by:
Hope for Depression Research Foundation
Alzheimer's Drug Development Foundation
NIH (MH125278, EB024495, AG066464)
Article History
Received: 8 June 2022
Accepted: 24 August 2022
First Online: 30 September 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies involving animals. The study was approved by the Johns Hopkins Investigational Review Board and Radiation Safety Committees. All subjects provided written informed consent.
: Not applicable.
: Under a license agreement between D&D Pharmatech and the Johns Hopkins University, the University, AGH, and MGP are entitled to royalty distributions related to the technology described in the study. MGP is a founder of and holds equity in D&D Pharmatech. He also is a paid consultant to the company. AGH is a paid consultant to the company. As the spouse of MGP, JMC shares his disclosures. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.